Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations

Register now for this complimentary educational meeting.

Gain expert perspective on optimal immunotherapy treatment of non-small-cell lung cancer in this 1-hour CME-certified meeting program, which affords the opportunity to interact with the faculty. This program will discuss using immune checkpoint inhibitors, adverse event management, and evaluating emerging therapeutic strategies with this class of agents.

Agenda

Overview of Immunotherapy for Advanced NSCLC

Clinical Application of Immunotherapy for Advanced NSCLC: Case Discussions

  • Which patients are candidates for checkpoint inhibitors
  • Choice of checkpoint inhibitor

Management of Treatment-Related Adverse Events

Emerging Therapeutic Strategies in Clinical Trials

Question and Answer Session

Events

Date / Time
Event Details
5/4/2017
5:00 PM

Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations

Baltimore, MD
University of Maryland Greenebaum Comprehensive Cancer Center Details

Faculty

Program Director
Leora Horn, MD

Associate Professor of Medicine
Clinical Director, Thoracic Oncology
Research Program
Assistant Vice Chairman for Faculty
Development

Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Program Director
Melissa L. Johnson, MD

Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Faculty
Hossein Borghaei, DO

Associate Professor
Chief,
Thoracic Medical Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Faculty
Jamie Chaft, MD

Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Benjamin Creelan, MD

Department of Thoracic Oncology
H. Lee Moffitt Cancer Center and Research
Institute
University of South Florida
Tampa, Florida

Faculty
Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Faculty
Daniel Morgensztern, MD

Assistant Professor
Division of Oncology
Department of Medicine
Washington University
St Louis, Missouri

Faculty
Rathi Pillai, MD

Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Faculty
Karen Reckamp, MD

Associate Professor
Medical Oncology and Therapeutics
Research
City of Hope Comprehensive Cancer Center
Duarte, California

Faculty
Howard West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

CME

Goal Statement

The goal of this activity is to improve participants’ competence in integrating immunotherapies into the treatment of patients with non-small-cell lung cancer.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who provide care for patients with non-small-cell lung cancer.

Learning Objectives

  • Plan treatment strategies using immune checkpoint inhibitors for patients with advanced NSCLC
  • Manage treatment-related adverse events associated with immune checkpoint inhibitors
  • Evaluate the available clinical data on emerging therapeutic strategies using immune checkpoint inhibitors for patients with advanced NSCLC

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.